Mercato chiuso -
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
22,07 USD | +6,77% | +11,92% | -27,62% |
08/08 | La perdita netta Q2 di Intellia Therapeutics si allarga, il fatturato cala | MT |
08/08 | Transcript : Intellia Therapeutics, Inc., Q2 2024 Earnings Call, Aug 08, 2024 |
Aggiungi a un elenco 0 selezionato | Fatturato ($) (Y-1) | Margine netto (Y-1) | Margine Operativo (Y-1) | ROE (Y-1) | ROA (Y-1) | Leva (indebitamento/EBITDA) (Y-1) | |
---|---|---|---|---|---|---|---|
36,28 Mln | -1,326.51% | -1,420.51% | -42.10% | -34.11% | 2x | ||
7,92 Mrd | +9.74% | +13.98% | +6.52% | +3.82% | 0.46x | ||
14,98 Mrd | +9.06% | +20.36% | +32.01% | +5.22% | 3.45x | ||
1,83 Mrd | -24.08% | -15.43% | - | -11.94% | 0.17x | ||
1,64 Mrd | +24.61% | +29.93% | +5.07% | +4.31% | 1.46x | ||
6,85 Mrd | -68.84% | -61.90% | -28.59% | -21.29% | 2.38x | ||
8,12 Mrd | +7.54% | +19.31% | +6.90% | +3.58% | 2x | ||
2,33 Mrd | +42.31% | +50.91% | +18.27% | +14.91% | -1.85x | ||
1,16 Mrd | +14.50% | +31.94% | +14.11% | +6.29% | 0.4x | ||
1,89 Mrd | +15.00% | +17.94% | +59.83% | +18.80% | -0.29x | ||
1,97 Mrd | +17.37% | +26.90% | +4.69% | +2.75% | 0.69x | ||
4,13 Mrd | +11.49% | +20.31% | +16.70% | +6.95% | 2.34x | ||
532 Mln | -40.26% | - | - | - | - | ||
11,58 Mln | -3,768.28% | -4,207.12% | -34.76% | -30.38% | 3.85x | ||
681 Mln | +19.38% | +22.41% | +9.00% | - | -1.79x | ||
788 Mln | -46.45% | -44.80% | -76.34% | -13.26% | 3.21x | ||
249 Mln | -203.30% | -194.99% | -157.13% | - | 0.99x | ||
1,04 Mrd | +27.44% | +35.35% | +9.95% | +7.09% | -1.51x | ||
1,63 Mrd | +13.88% | +14.92% | +13.86% | +6.82% | 1.36x | ||
Media | 3,04 Mrd | -277,13% | -313,36% | -8,35% | -1,90% | 1,07x | |
Media ponderata per Capi. | 5,4 Mrd | -101,18% | -106,36% | +3,82% | -0,17% | 1,27x |
- Borsa valori
- Azioni
- Azione NTLA
- Settore Intellia Therapeutics, Inc.
- Confronti finanziari
MarketScreener is also available in this country: United States.
Switch edition